Physician profile
Robert V Kellow
NPI 1497870828
$1,759.19
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $524 · 2021: $759.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $403.37 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $302.79 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.82 | 2019-2021 | |
| Adlon Therapeutics L.P. | $191.04 | 2019-2021 | |
| Kaleo, INC. | $161.57 | 2019-2021 | |
| Corium, LLC | $80.44 | 2021 | |
| Glaxosmithkline, LLC. | $76.42 | 2019-2020 | |
| Shire North American Group INC | $61.15 | 2019 | |
| Sanofi Pasteur INC. | $51.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $47.09 | 2019-2021 | |
| Genentech USA, INC. | $46.05 | 2020-2021 | |
| Tris Pharma INC | $41.76 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $28.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.45 | 2019 | |
| Seqirus USA INC | $19.44 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $16.19 | 2020 | |
| Cranial Technologies, INC | $11.25 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kellow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.